

Walk, Roger A.

From: Stern, Warren [Warren.Stern@parexel.com]
Sent: Friday, July 14, 2000 2:15 PM
To: 'ROGERWALK@YAHOO.com'
Cc: Steuernagel, Carl; Roethig, Hans-Juergen
Subject: BIOMARKER STRATEGIES

Electronic Storage No.:									
8	7								
Worldwide Scientific Affairs									



Stern4.doc

Dr. Roger Walk

Director
Worldwide Scientific Affairs
Philip-Morris
PO Box 2361
Richmond, VA 23261

Dear Dr. Walk:

Parexel has recently concluded an alliance with a Massachusetts based company, MassTrace, which specializes in the use of biomarkers in human clinical trials. While their main orientation is the use of biomarkers in drug related clinical trials, the knowledge they have gained from many years of thinking and working on these issues, and, from the standpoint of selecting practical assays which provide noninvasive indices of enzymatic activity in patients or normal volunteers may be useful to Philip-Morris. Since MassTrace is bound by a secrecy agreement to Parexel, I took the liberty of seeking their expert opinion regarding the biomarker strategy for the smoking study being designed by Philip-Morris and collaborators. The comments and suggestions of the MassTrace biomarker experts are provided in the attachment.

If you would like to meet with their lead scientist, Dr. Alfred Ajami, to review the thoughts given in their proposal, or to discuss other matters relative to the biomarker strategy, we would be please to set up a meeting.

Best regards,

Warren Stern, PhD
Sr. Vice President
Scientific and Medical Services

cc: P. Leone, A. Ajami (MassTrace)
C. Steuernagel
H-J. Roethig, MD